Vijaya Diagnostic Centre cash flow

Latest FY26

Cash from operations: ₹271cr+20.5% on FY25
Capital spending: ₹183cr+91.2% on FY25
Free cash flow: ₹87.9cr−31.8% on FY25
Cash from financing: −₹69.5cr−₹52.0 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	91.8	70.6	57.0	61.7
	—	0.0	0.0	0.0	1.0
	—	31.3	24.5	22.0	19.4
	—	−5.6	0.0	−6.0	−8.3
	—	−4.5	0.0	3.2	−3.9
	—	1.7	1.6	0.9	0.7
	—	1.7	−0.3	−1.5	−0.9
	—	−9.5	−17.8	−15.7	−0.9
	—	0.0	0.0	0.0	−0.1
	—	0.0	0.3	−2.3	2.2
	—	−7.9	1.5	−4.6	0.0
	—	−1.4	0.0	1.4	2.6
	—	0.0	−11.9	−1.9	0.0
	—	−18.4	0.0	0.0	−2.1
	—	4.5	−0.1	3.3	7.0
	—	1.6	1.0	1.5	−1.8
	—	0.0	1.9	0.0	0.0
	—	0.0	0.0	1.1	0.0
	—	4.8	0.0	0.0	0.4
Cash from operating activities
	251	233	193	159	114
	—	90.2	71.2	58.5	77.3
	—	323	264	217	191
	—	52.2	39.9	33.9	26.2
	—	271	224	183	165
Cash from investing activities
	—	183	95.6	88.0	125
	—	2.8	2.9	3.3	0.3
	—	0.0	0.0	0.0	88.7
	—	0.0	0.0	0.0	80.0
	—	0.0	0.0	148	0.0
	—	6.4	3.3	7.4	6.4
	—	−0.8	−92.5	82.5	0.0
	—	−174	−182	−142	−110
Cash from financing activities
	—	0.0	0.0	0.0	1.2
	—	3.2	4.1	3.1	0.0
	—	0.0	0.0	0.0	0.6
	—	21.5	45.9	37.4	0.0
	—	—	—	0.0	32.2
	—	30.7	0.0	0.0	0.0
	—	20.5	10.3	10.2	10.2
	—	−69.5	−52.0	−44.5	−41.9
	—	26.9	−9.4	−3.6	13.1
	—	26.9	−9.4	−3.6	13.1
	—	—	—	22.2	24.2
Reference items
	362	337	273	221	182
	42.2%	41.4%	40.1%	40.3%	39.6%
	87.9	87.9	129	95.3	39.8
	—	57.2	—	—	—
	₹8.54	₹8.54	₹12.53	₹9.27	₹3.86
	171.45×	—	—	—	—
	—	1.56×	1.56×	1.53×	1.93×
	—	52.2	39.9	33.9	26.2
	—	30.7	—	—	0.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIJAYA₹1,464.20

Vijaya Diagnostic Centre Ltd.

· Pharma & Health

₹ CrorePeersTHYROCARE METROPOLIS LALPATHLAB RAINBOW POLYMED PFIZER ONESOURCE KIMSMcap ₹15,066 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	61.7	57.0	70.6	91.8	—
+ Impairment Loss / (Reversal)	1.0	0.0	0.0	0.0	—
+ Finance Costs	19.4	22.0	24.5	31.3	—
+ Interest Income	-8.3	-6.0	0.0	-5.6	—
+ Fair Value (Gains) / Losses	-3.9	3.2	0.0	-4.5	—
+ Share-based Payments	0.7	0.9	1.6	1.7	—
+ Other Non-cash Items	-0.9	-1.5	-0.3	1.7	—
+ Other — Cash Effects are Investing / Financing	-0.9	-15.7	-17.8	-9.5	—
+ Other Reconciling Items	-0.1	0.0	0.0	0.0	—
Changes in Working Capital
+ Inventories	2.2	-2.3	0.3	0.0	—
+ Trade Receivables — Current	0.0	-4.6	1.5	-7.9	—
+ Other Financial Assets — Current	2.6	1.4	0.0	-1.4	—
+ Other Current Assets	0.0	-1.9	-11.9	0.0	—
+ Other Non-current Assets	-2.1	0.0	0.0	-18.4	—
+ Trade Payables — Current	7.0	3.3	-0.1	4.5	—
+ Other Financial Liabilities — Current	-1.8	1.5	1.0	1.6	—
+ Other Current Liabilities	0.0	0.0	1.9	0.0	—
+ Provisions — Current	0.0	1.1	0.0	0.0	—
+ Provisions — Non-current	0.4	0.0	0.0	4.8	—
Cash from Operating Activities
Profit Before Tax (per I/S)	113.5	158.7	193.2	232.7	251.4
+ Total Adjustments (incl. Working Capital)	77.3	58.5	71.2	90.2	—
Cash from Operations (pre-tax)	190.8	217.2	264.4	322.8	—
+ Income Taxes Paid	26.2	33.9	39.9	52.2	—
Cash from Operating Activities	164.6	183.3	224.5	270.6	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	124.8	88.0	95.6	182.7	—
+ Disp of Fixed Assets	0.3	3.3	2.9	2.8	—
+ Disp of Other Long-term Assets	88.7	0.0	0.0	0.0	—
+ Purchase of Investments (Equity / Debt)	80.0	0.0	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	147.5	0.0	0.0	—
+ Interest Received — Investing	6.4	7.4	3.3	6.4	—
+ Other Inflows / (Outflows) — Investing	0.0	82.5	-92.5	-0.8	—
Cash from Investing Activities	-109.6	-142.3	-181.9	-174.2	—
Cash from Financing Activities
+ Proceeds from Other Equity Instruments	1.2	0.0	0.0	0.0	—
+ Proceeds from Exercise of Stock Options	0.0	3.1	4.1	3.2	—
+ Repayment of Borrowings	0.6	0.0	0.0	0.0	—
+ Payment of Lease Liabilities	0.0	37.4	45.9	21.5	—
+ Payment of Finance Lease Liabilities	32.2	0.0	—	—	—
+ Interest Paid	0.0	0.0	0.0	30.7	—
+ Dividends Paid	10.2	10.2	10.3	20.5	—
Cash from Financing Activities	-41.9	-44.5	-52.0	-69.5	—
Net Changes in Cash (pre-FX)	13.1	-3.6	-9.4	26.9	—
Net Changes in Cash	13.1	-3.6	-9.4	26.9	—
Closing Cash	24.2	22.2	—	—	—
Reference Items
EBITDA	182.0	220.9	273.2	336.9	361.9
EBITDA Margin %	39.64	40.32	40.10	41.38	42.23
Free Cash Flow (CFO − Capex)	39.8	95.3	128.9	87.9	87.9
Free Cash Flow to Equity	—	—	—	57.2	—
Free Cash Flow per Basic Share	3.86	9.27	12.53	8.54	8.54
Price to Free Cash Flow	—	—	—	—	171.45
Cash Flow to Net Income	1.93	1.53	1.56	1.56	—
Cash Paid for Taxes	26.2	33.9	39.9	52.2	—
Cash Paid for Interest	0.0	—	—	30.7	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.